Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Sold by Nuveen Asset Management LLC

Nuveen Asset Management LLC lessened its position in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 17.6% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 414,104 shares of the biopharmaceutical company's stock after selling 88,468 shares during the quarter. Nuveen Asset Management LLC owned approximately 0.26% of Ocular Therapeutix worth $3,536,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Deep Track Capital LP raised its holdings in Ocular Therapeutix by 0.9% in the 4th quarter. Deep Track Capital LP now owns 12,836,282 shares of the biopharmaceutical company's stock valued at $109,622,000 after acquiring an additional 114,822 shares in the last quarter. Vanguard Group Inc. increased its holdings in Ocular Therapeutix by 1.2% during the 4th quarter. Vanguard Group Inc. now owns 8,483,913 shares of the biopharmaceutical company's stock worth $72,453,000 after purchasing an additional 99,730 shares in the last quarter. Deltec Asset Management LLC boosted its stake in shares of Ocular Therapeutix by 0.6% during the 4th quarter. Deltec Asset Management LLC now owns 2,616,373 shares of the biopharmaceutical company's stock worth $22,344,000 after buying an additional 16,300 shares during the last quarter. Artisan Partners Limited Partnership raised its holdings in shares of Ocular Therapeutix by 26.4% in the 4th quarter. Artisan Partners Limited Partnership now owns 1,334,702 shares of the biopharmaceutical company's stock valued at $11,398,000 after purchasing an additional 278,610 shares during the period. Finally, Northern Trust Corp raised its holdings in Ocular Therapeutix by 5.5% in the 4th quarter. Northern Trust Corp now owns 1,314,871 shares of the biopharmaceutical company's stock valued at $11,229,000 after acquiring an additional 68,174 shares during the period. 59.21% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on OCUL. William Blair started coverage on shares of Ocular Therapeutix in a research report on Tuesday, April 8th. They set an "outperform" rating for the company. HC Wainwright reiterated a "buy" rating and set a $15.00 target price on shares of Ocular Therapeutix in a research note on Thursday, May 29th. JMP Securities set a $19.00 price objective on Ocular Therapeutix in a research note on Tuesday, March 4th. Royal Bank of Canada started coverage on Ocular Therapeutix in a research report on Tuesday, March 18th. They set an "outperform" rating and a $17.00 price target on the stock. Finally, Needham & Company LLC lowered their price target on Ocular Therapeutix from $15.00 to $14.00 and set a "buy" rating for the company in a research report on Tuesday, May 6th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $16.25.

Ocular Therapeutix Stock Performance

OCUL traded up $0.22 on Tuesday, reaching $8.33. The stock had a trading volume of 2,951,070 shares, compared to its average volume of 1,407,828. The business's 50-day moving average price is $7.38 and its two-hundred day moving average price is $7.89. The company has a market cap of $1.33 billion, a P/E ratio of -6.31 and a beta of 1.51. Ocular Therapeutix, Inc. has a 12-month low of $4.79 and a 12-month high of $11.78. The company has a current ratio of 13.01, a quick ratio of 12.94 and a debt-to-equity ratio of 0.19.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last announced its earnings results on Monday, March 3rd. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.05). Ocular Therapeutix had a negative return on equity of 45.18% and a negative net margin of 283.74%. The business had revenue of $17.08 million for the quarter, compared to analyst estimates of $16.89 million. Sell-side analysts forecast that Ocular Therapeutix, Inc. will post -0.98 earnings per share for the current year.

Insider Activity

In related news, insider Pravin Dugel sold 21,219 shares of the firm's stock in a transaction dated Friday, May 23rd. The shares were sold at an average price of $7.18, for a total value of $152,352.42. Following the completion of the sale, the insider now owns 3,499,099 shares in the company, valued at $25,123,530.82. This trade represents a 0.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Richard L. Md Lindstrom purchased 10,000 shares of the business's stock in a transaction dated Thursday, May 8th. The shares were purchased at an average cost of $6.96 per share, with a total value of $69,600.00. Following the purchase, the director now directly owns 172,704 shares in the company, valued at approximately $1,202,019.84. The trade was a 6.15% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders sold 29,079 shares of company stock valued at $208,739. Insiders own 2.30% of the company's stock.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.